Nov 08, 2023 / 10:00PM GMT
Eliana Rachel Merle - UBS Investment Bank, Research Division - Analyst
Hi. Good afternoon, everyone. Thank you so much for joining us here. I'm Ellie Merle. I'm one of the biotech analysts here at UBS. Very happy to have Madrigal Pharmaceuticals here with us today. Joining us from Madrigal is the new CEO, Bill Sibold, Chief Executive Officer. Thank you so much for joining us during what appears to be a well-attended happy hour. I was told to now call this a fireside chat. And so with that, I'll turn it to you and ask what led to your decision to join Madrigal?
William J. Sibold - Madrigal Pharmaceuticals, Inc. - CEO, President & Director
Well, Ellie, first of all, thanks for having me, having us here. It's a real pleasure to spend some time. Look, I'm 7 weeks into the new job. And I have to say, I've been waiting for that moment where I say, "Boy, is this the right thing to do?" And I can tell you, along the whole way, it's getting more and more exciting.
I think it's very rare in the industry to have an opportunity where there is a disease of such
Madrigal Pharmaceuticals Inc at UBS BioPharma Conference Transcript
Feb 07, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers